Cansino Biologics Inc-h Stock price
AI Insights on Cansino Biologics Inc-h
Insights
Is Cansino Biologics Inc-h a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,100 stocks worldwide.
Key metrics
Cansino Biologics Inc-h Stock Analysis
Analyst Opinions
7 Analysts have issued a Cansino Biologics Inc-h forecast:
Analyst Opinions
7 Analysts have issued a Cansino Biologics Inc-h forecast:
Cansino Biologics Inc-h Events
Past Events
|
OCT
27
Q3 2026 Earnings Call
2 days ago
|
Don't miss a Thing! We will send you all news about Cansino Biologics Inc-h directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
CanSino Biologics Inc is a CN-based company operating in Biotechnology industry. The company is headquartered in Tianjin, Tianjin and currently employs 1,134 full-time employees. The company went IPO on 2019-03-28. CanSino Biologics Inc is a China-based company primarily engaged in the research and development, production, and commercialization of human vaccine products. The Company’s products and product pipeline under research include multiple vaccine varieties such as meningitis, pneumonia, diphtheria, tetanus, and pertussis (DPT), coronavirus disease 2019 (COVID-19), Ebola virus disease, poliomyelitis, herpes zoster, tuberculosis and others. The firm is also engaged in the research and development of pharmaceutical production processes. The firm conducts its business in the domestic and overseas markets.
| Head office | China |
| CEO | Mr. Yu |
| Employees | 1,134 |
| Website | www.cansinotech.com |


